Skip to main content

NEO NeoGenomics, Inc.

Healthcare

16.88

Close 10/14

52W 7.07 20.15
Loading candles…

Is NeoGenomics, Inc. a buy? Fundamentals and valuation first

As of 2026-10-14

Growth: Good, Momentum: Strong.

Quality Neutral All 3 indicators are Average.
ROE, TTM (%) -6.6 32th percentile Average
Operating margin, TTM (%) -8.63 26th percentile Average
FCF margin, TTM (%) -0.96 34th percentile Average
Growth Good Revenue growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 11.19 64th percentile Good
Momentum Strong All 2 indicators are Top.
60-day return (%) 16.82 90th percentile Top
240-day return (%) 64.2 91th percentile Top
Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 46,253,539 80th percentile Top
60-day annualized volatility (%) 61.77 65th percentile Average

NeoGenomics, Inc. (NEO) today

2 quant signals active · As of 2026-10-14

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

NeoGenomics, Inc. (NEO) peers and tracking

Watchlist

This page refreshes daily after the close. Add NeoGenomics, Inc. to your watchlist to track signal changes on your next visit.

NeoGenomics, Inc. (NEO) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 95.93%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

20 historical occurrences (since 2016-07-08)
Average forward return after Top-quintile 6-month momentum。20-day: Win 65%, Sample 20, Median +7.99%, Excess +1.73%, Beat mkt rate 65%；60-day: Win 63.2%, Sample 19, Median +6.73%, Excess +6.74%, Beat mkt rate 63.2%；120-day: Win 52.6%, Sample 19, Median +2.74%, Excess +2.72%, Beat mkt rate 47.4%

120 days after: historical avg +10.85%

20-day +2.47%
60-day +7.26%
120-day +10.85%
20-day
60-day
120-day
Win
65%
63.2%
52.6%
Sample
20
19
19
Median
+7.99%
+6.73%
+2.74%
Excess
+1.73%
+6.74%
+2.72%
Beat mkt rate
65%
63.2%
47.4%

Over 19 occurrences, 120-day forward avg gained 10.85%, beat the market by 2.72 pts; win rate 52.6%.

Filed revenue acceleration

Active · now 11.19%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

12 historical occurrences (since 2019-05-08)
Average forward return after Filed revenue acceleration。20-day: Win 66.7%, Sample 12, Median +4.02%, Excess +4.71%, Beat mkt rate 66.7%；60-day: Win 63.6%, Sample 11, Median +1.84%, Excess +3.47%, Beat mkt rate 36.4%；120-day: Win 60%, Sample 10, Median +4.71%, Excess -1.65%, Beat mkt rate 50%

120 days after: historical avg +5.9%

20-day +5.15%
60-day +7.95%
120-day +5.9%
20-day
60-day
120-day
Win
66.7%
63.6%
60%
Sample
12
11
10
Median
+4.02%
+1.84%
+4.71%
Excess
+4.71%
+3.47%
-1.65%
Beat mkt rate
66.7%
36.4%
50%

Over 10 occurrences, 120-day forward avg gained 5.9%, lagged the market by 1.65 pts; win rate 60%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 98,465 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.50%, a 58.4% positive-return rate, and +3.15 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

23 times historically; 60-day forward avg -0.82%, win rate 50%, beating the market by -2.48 pts on average.

Continue researching NeoGenomics, Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.
  • This is an American depositary receipt (ADR). The data does not say how many ordinary shares each ADR represents, so per-share and market-value metrics (P/E, price/book, free-cash-flow yield, EPS growth and earnings surprises) are not computed.
  • ADRs listed on NYSE or NASDAQ are covered as a separate group selected by dollar volume, in addition to the common-stock universe; the 6-month momentum signal ranks each ADR against the liquid US common stocks.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.